经导管植入^(125)I放射性粒子治疗肝癌伴门静脉癌栓19例  

Percutaneous transcatheter implantation of ^(125)iodine seeds for the treatment of liver cancer associated with portal vein tumor thrombus: initial experience in 19 cases

作　　者：刘岩[1] 刘瑞宝[1] 王平[1] 李世杰[1] 沈海洋[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院介入放射科,150040

出　　处：《介入放射学杂志》2014年第1期35-37,共3页Journal of Interventional Radiology

摘　　要：目的评估经导管植入125I放射性粒子治疗肝癌伴门静脉癌栓的可行性及疗效。方法 19例原发性肝癌伴门静脉癌栓患者行门静脉125I粒子植入术。手术方法采用超声导引穿刺门静脉,透视下经导管植入125I放射性粒子,粒子间距8 mm,每例患者粒子植入数量8~30粒。评价指标包括手术成功率、术后并发症、肝肾功能及血常规改变、癌栓抑制情况。结果所有患者125I粒子均成功植入,未发生手术相关严重并发症。术后随访3~22个月,门静脉癌栓均明显缩小。结论经导管植入125I放射性粒子治疗肝癌伴门静脉癌栓方法可行,可有效治疗门静脉癌栓。Objective To evaluate the feasibility and therapeutic efficacy of percutaneous transcatheter implantation of 125iodine seeds in treating liver cancer associated with portal vein tumor thrombus. Methods Nineteen patients with primary hepatocellular carcinoma complicated by portal vein tumor thrombus received implantation of 125iodine seeds via portal vein. The puncturing of portal vein was guided by ultrasound. Under fluoroscopic guidance the 125iodine seeds were implanted within the portal vein tumor thrombus at 8 mm distance. The number of 125iodine seeds used in one procedure was 8 to 30 in total. The technical success rate, the postoperative complications, the hepatic and renal functions as well as routine blood test, and the suppression of portal vein tumor thrombus were determined, and the results were analyzed. Results The implantation of 125I seeds was successfully accomplished in all the patients. No serious procedure-related complications occurred. During the follow-up period lasting for 3 - 22 months, the portal vein tumor thrombus showed a significant shrinkage in all patients. Conclusion For the treatment of portal vein tumor thrombus, percutaneous transcatheter implantation of125iodine seeds is clinically feasible and effective.

关 键 词：肝癌 门静脉癌栓 ^125I粒子 

分 类 号：R735.7[医药卫生—肿瘤]